About 32 results found for searched term "UT-11" (0.107 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10306 | Bavdegalutamide (ARV-110) | Androgen Receptor |
| ARV110 | ||
| Bavdegalutamide (ARV-110) is an oral, specific androgen receptor (AR) PROTAC degrader. | ||
| M18496 | Kizuta saponin K11 | Others |
| Kizuta saponin K11 | ||
| M42035 | UT-11 | PGE synthase |
| UT-11 is a potent and brain-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor. | ||
| M54028 | (6S, 9S, 12S)-Benzyl 12-benzyl-9-isobutyl-2, 2-dimethyl-4, 7, 10-trioxo-6-phenethyl-3-oxa-5, 8, 11-triazatridecan-13-oate | Amino Acid Derivatives |
| (6S,9S,12S)-Benzyl 12-benzyl-9-isobutyl-2,2-dimethyl-4,7,10-trioxo-6-phenethyl-3-oxa-5,8,11-triazatridecan-13-oate is a phenylalanine derivative. | ||
| M2104 | BYL-719 | PI3K |
| Alpelisib; BYL719 | ||
| Alpelisib (Byl-719) is an effective, selective PI3Kα inhibitor with oral activity. Alpelisib (Byl-719) was targeted to PIK3CA mutated carcinoma. The IC50 of Alpelisib (Byl-719) against P110 α, P110 γ, p110δ and P110 β were 5 nM, 250 nM, 290 nM and 1200 nM, respectively. It has antitumor activity. | ||
| M2424 | AZD9291 (Osimertinib) | EGFR/HER2 |
| Osimertinib; Mereletinib | ||
| Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. | ||
| M3437 | Cilomilast | PDE |
| SB-207499 | ||
| Cilomilast is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. | ||
| M3970 | Scutellarin | STAT |
| Scutellarin, an active flavone isolated from Scutellaria baicalensis, is active against HIV-1IIIB, HIV-1(74V) and HIV-1KM018 with EC50s of 26 μM, 253 μM and 136 μM, respectively. Scutellarin inhibited caspase-11 activation and pyroptosis in macrophages at least partly via regulating the PKA signaling pathway. | ||
| M4376 | Forsythin | Cytochrome P450 (e.g. CYP17) |
| Phillyrin is isolated from forsythia and has antibacterial and anti-inflammatory properties. Phillyrin can potentially induce CYP1A2 and CYP2D1 in rats, but does not affect THE activities of CYP2C11 and CYP3A1/2. Phillyrin has activity against influenza A virus. | ||
| M6086 | SBI-0206965 | ULK |
| SBI 0206965; SBI0206965 | ||
| SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50 of 108 nM for ULK1 kinase activity and 711 nM for the highly related kinase ULK2 . | ||
| M8199 | SR11237 | RAR/RXR |
| SR11237 is a retinoid X receptor (RXR) selective agonist without any RAR activity that leads to the formation of RXR/RXR homodimers and activation of reporter genes containing RXR response elements. In addition, SR11237 significantly promotes reprogramming. | ||
| M9016 | Ezutromid | Cytochrome P450 (e.g. CYP17) |
| BMN-195; SMT C1100 | ||
| Ezutromid (BMN-195, SMT C1100) is a first-in-class oral bioavailable utrophin translational modulator with an EC50 value of 0.4 uM. | ||
| M10025 | Zanubrutinib | BTK |
| BGB-3111 | ||
| Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). | ||
| M10035 | Semaglutide | GLP Receptor |
| Rybelsus; Ozempic; NN9535; OG217SC; NNC 0113-0217 | ||
| Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting human GLP-1 analog, it is also a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM). | ||
| M10434 | Olutasidenib (FT-2102) | Isocitrate Dehydrogenase (IDH) |
| FT-2102 | ||
| Olutasidenib (FT-2102) is a highly potent and selective, orally active, brain penetrant mutant Isocitrate dehydrogenase 1 (IDH1) inhibitor, with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively. | ||
| M11442 | Divarasib | Ras |
| GDC-6036 | ||
| Divarasib (GDC-6036) is an orally active, selective, covalently mutated KRAS G12C inhibitor with an IC50<0.01 μM for K-Ras G12C. GDC-6036 has an EC50 of 2 nM in K-Ras G12C-alkylated HCC1171 cells. can be used in studies related to non-small cell lung cancer ( NSCLC) related studies. | ||
| M14472 | Luteolin 7-O-glucuronide | MMP |
| Luteolin 7-glucuronide | ||
| Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively. | ||
| M14879 | (±)-Zanubrutinib | BTK |
| (±)-BGB-3111 | ||
| (±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. | ||
| M20443 | 4-Butylresorcinol | Others |
| 4-Butylresorcinol is a phenol derivative which can inhibit tyrosinase with IC50 of 11.27 μM. | ||
| M20810 | PBD-150 | Amyloid |
| PBD-150 is a potent human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor with Ki of 60 nM. | ||
| M20864 | L-2-Hydroxyglutaric acid disodium | Histone demethylase |
| (S)-2-Hydroxyglutaric acid disodium, L-2-Hydroxyglutarate disodium, LGA, L-2HG | ||
| L-2-Hydroxyglutaric acid disodium ((S)-2-Hydroxyglutaric acid disodium, L-2-Hydroxyglutarate disodium, LGA, L-2HG) is an epigenetic modifier and a putative oncometabolite in kidney cancer that inhibits histone demethylases and hence promotes histone methylation. L-2-Hydroxyglutaric acid disodium is also an inhibitor of mitochondrial creatine kinase (Mi-CK) with Km and Ki of 2.52 mM and 11.13 mM, respectively. | ||
| M21146 | LUT014 | Raf |
| LUT014, a B-Raf inhibitor with an IC50 value of 11.7 nM, was developed for the study of reducing acne-like lesions associated with EGFR inhibitors at restricted doses. | ||
| M21153 | MG-277 | PROTAC |
| MG-277 is a molecular gel degrader that efficiently induces degradation of the translation termination factor GSPT1 based on Cereblon E3 ligands with a DC50 of 1.3 nM. MG-277 inhibits tumor cell growth in a non-p53 manner with an IC50 of 3.5 nM and 3.4 nM for RS4;11 cells and p53 mutant RS4;11/IRMI-2 cells, respectively. MG-277 exhibited potent anticancer activity. | ||
| M21257 | MK-6884 | Others |
| MK-6884 is an M4 muscarinic receptor orthomodulator (PAM) with a Ki value of 0.19 nM. MK-6884 is used in the study of neurodegenerative diseases. MK-6884 can be used as a positron emission computed tomography imaging agent with 11C radiolabeling. | ||
| M21374 | AZ 1729 | Others |
| AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator that acts as a direct transmutation agonist and a positive transmutation modulator.AZ1729 increases the activity of endogenous short-chain fatty acid propionate in the Gi-mediated pathway but not in the Gq/G11-transduced pathway. | ||
| M21389 | JNJ-55511118 | Others |
| JNJ-55511118 is an AMPA receptor negative regulator containing transmembrane AMPA receptor regulatory protein γ8 (TARP-γ8). 1 It inhibits glutamate-induced calcium flux in HEK293F cells that were cotransfected with TARP-γ8 and GluA1o, GluA1i, GluA2i, GluA3o, or GluA4o (IC50s = 11.22, 12.3, 7.41, 38.02, and 15.85 nM, respectively). | ||
| M22464 | M4205 | c-Kit |
| M-4205; IDRX-42 | ||
| M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. | ||
| M24740 | Mipeginterferon alfa-2b | Others |
| Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa. | ||
| M24759 | Aprutumab | FGFR |
| BAY 1179470 | ||
| Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. | ||
| M27821 | Renzapride | 5-HT Receptor |
| BRL 24924 | ||
| Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study. | ||
| M27869 | CCT241161 | Raf |
| CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity. | ||
| M28266 | KL-11743 | GLUT |
| KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
